BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

MADRID — BioN­Tech is back with new da­ta to sup­port its BNT211 pro­gram in sol­id tu­mors af­ter a man­u­fac­tur­ing tweak. The com­pa­ny is now re­view­ing plans for the pos­si­bil­i­ty of a reg­is­tra­tional Phase II tri­al in germ cell tu­mors for next year, as well as the po­ten­tial of a mid-stage in­ves­ti­ga­tion in ovar­i­an can­cer.

BNT211, which com­bines BioN­Tech’s ther­a­peu­tic RNA vac­cine CAR­Vac with a Claudin-6 CAR-T cell ther­a­py, now has a more au­to­mat­ed man­u­fac­tur­ing process for its CAR-T and in­creased dos­ing for the vac­cine por­tion. The CAR-T is “more au­to­mat­ed, more scal­able and more ro­bust,” added Ben­jamin Rengstl, BioN­Tech di­rec­tor of clin­i­cal de­vel­op­ment and im­munore­cep­tor ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER